Selective oral CDK2 degrader shows promise in breast cancer models
According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer.
Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas.
The data demonstrate that the company’s CDK2-directed MGD, MRT-9643, has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression.
“Degrading CDK2 in conjunction with CDK4/6 inhibition has the potential to provide more sustained responses in patients with HR-positive/HER2-negative breast cancer. While currently approved CDK4/6 inhibitors offer clinical benefit, patients often relapse as tumours become reliant on the CDK2 pathway. However, attempts to inhibit CDK2 with conventional modalities have led to substantial toxicities, likely due to inadequate target specificity,” said Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics.
“Our results demonstrate that MRT-9643 is a highly selective oral CDK2 degrader that could potentially avoid many of the dose-limiting toxicities associated with less selective CDK2 inhibitors. Additionally, in preclinical models of HR-positive/HER2-negative breast cancer, the combination of our CDK2-targeted MGD with either a CDK4/6 inhibitor or a CDK4/6 inhibitor plus an endocrine therapy drove deep tumour regression. We look forward to advancing our CDK2 MGD programme towards a development candidate nomination in H1 2025.”
Sustained clinical response
Summary of findings:
- In cellular assays, MRT-9643 induced deep CDK2 degradation, resulting in CDK2-dependent cancer cell growth inhibition.
- MRT-9643 engages CDK2 through a novel binding mode that does not utilise the catalytic site typically engaged by catalytic-site inhibitors, enabling superior selectivity over conserved CDKs and other kinases.
- MRT-9643 demonstrated superior selectivity as compared to several clinical-stage small molecule CDK2 inhibitors evaluated.
- The combination of MRT-9643 and ribociclib, an FDA-approved CDK4/6 inhibitor, delayed resistance to CDK4/6 inhibition both in vitro and in vivo.
- When dosed orally in preclinical models of HR-positive/HER2-negative breast cancer, MRT-9643 drove deep tumour regression in combination with a CDK4/6 inhibitor or triple combination with a CDK4/6 inhibitor and endocrine therapy (fulvestrant), resulting in enhanced downstream pathway suppression as compared to a CDK4/6 inhibitor alone.
Cyclin-dependent kinase 2 (CDK2) is a key driver of cell cycle progression in cancer, acting in coordination with CDK4 and CDK6 to drive cell proliferation. Targeting CDK2 in conjunction with CDK4/6 inhibition has the potential to provide more sustained clinical responses.
Diana Spencer, Senior Digital Content Editor, DDW
